http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003506716-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-723 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2000-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2003506716-A |
| titleOfInvention | Diagnostic kit and its use |
| abstract | (57) [Summary]nThe present invention relates to diagnostic kits for stratifying patients to treat hormone-dependent benign and malignant neoplasia and uses thereof. The kit comprises, on the one hand, antibodies to proliferation markers, preferably Ki-67 proteins, MCM, PCNA, cyclins, phosphorylated histones, in particular for Ki-67 proteins, and the other a hormone receptor, such as an estrogen receptor, a mAb. Antibodies against apoptosis markers such as caspase-cleaved cytokeratin 18, CD30 and bcl-2; a marker for transformed cells or a second marker selected from the group of tumor cell markers, such as Her-2 / neu, defined by Comprising. The marker indices generated with the aid of the antibody (eg, Ki-67 marker index and hormone receptor status) can be related to each other and can help determine the optimal form of treatment. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019168085-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200128110-A |
| priorityDate | 1999-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 139.